Jade Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026New drug licenses expand the company's pipeline and potential revenue from royalties on future sales.
CFO appointment shows leadership stability needed to manage company finances and investor relations.
Governance change affects how legal disputes are handled, reducing potential litigation costs.
New cash funds research and operations; investors should know their ownership stake gets diluted.
Official pricing document confirms the company's fundraising terms and potential total proceeds.
Initial offering documents show the company is preparing to raise capital through multiple security types.
Positive early trial results boost confidence that the drug candidate could work in real patients.
Stocky reads Jade Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Jade Biosciences, Inc.'s most recent tracked filing was a 8-K on 1 Jul 2026: Gains exclusive license to antibody technology from Paragon Therapeutics.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.